KPV Lys-Pro-Val Tripeptide

KPV is a naturally occurring tripeptide consisting of the amino acids lysine, proline, and valine. It corresponds to the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). Preclinical studies have investigated how KPV interacts with inflammatory signalling pathways, particularly NF-κB-mediated cytokine expression, and its potential role in tissue-repair and mucosal repair models.

KPV is a tripeptide consisting of the amino acids lysine, proline, and valine (Lys-Pro-Val), representing the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH). Alpha-MSH is a 13-amino-acid endogenous neuropeptide involved in pigmentation, inflammation, and energy regulation, derived from pro-opiomelanocortin (POMC). KPV was identified as the minimum active sequence of α-MSH required to retain anti-inflammatory activity in certain preclinical models, offering a smaller and more tractable research tool than the full 13-residue α-MSH while targeting overlapping biological pathways.

Preclinical research on KPV has focused primarily on inflammatory signalling in cell culture and rodent models. Studies have examined its effects on pro-inflammatory cytokine production — particularly IL-1β, TNF-α, and IL-6 — in stimulated macrophage and monocyte cell lines, with researchers investigating its interaction with NF-κB signalling pathways associated with inflammatory gene transcription. Research in gastrointestinal biology has investigated KPV’s effects in colitis models and intestinal epithelial cell culture, examining its interaction with gut epithelial tight junction function and mucosal immune responses.

In dermatological and skin biology research, KPV has been studied in models of skin inflammation and tissue repair mechanisms, with cell studies examining its effects on keratinocyte cytokine production and dermal fibroblast activity. KPV is thought to act at least partly through melanocortin receptor interaction — MC1R and MC3R binding studies have been reported — though its mechanism in gut epithelial models may involve additional receptor-independent pathways. Its small tripeptide size gives it potentially favourable cell permeability characteristics in experimental settings. Velox Peptides supplies KPV at ≥99% HPLC-verified purity as a lyophilised research reagent. Not for human or veterinary consumption.

Summary paraphrased from the peer-reviewed preclinical literature. For in vitro research use only. For source citations, email support@veloxpeps.com.

Every batch of KPV is third-party HPLC-tested prior to dispatch. Batch documentation is available on request.

Previous batch CoAs are archived in the CoA library. For batch-specific CoA requests prior to purchase, contact support@veloxpeps.com.

KPV is sold by Velox Peptides (CRP Labs Ltd, UK company no. NI738125) and dispatched from the UK. Choose a vial size, pay on one page, and your order is dispatched the next working day.

• Delivery: Royal Mail Tracked 24 (1–2 working days, £5.99, free over £100) or Tracked 48 (2–3 working days, £3.80). See shipping.
• Payment: Pay by Bank through FCA-authorised open banking, or bank transfer. No card details needed.
• Testing: See the batch testing details above and past reports in the CoA library.
• Research use only: Supplied as a research reagent for in vitro use. Not for human or veterinary consumption. See our Research Use Policy.